Cullinan Oncology Inc - ESG Rating & Company Profile powered by AI
The Disclosure rating covers 17 UN Sustainable Development Goals including: 'Clean Water & Sanitation', 'Responsible Production & Consumption' and 'Life on Land'. The report of Cullinan Oncology Inc uses intelligence from across the internet as well as from available disclosures by Cullinan Oncology Inc. Other corporations in the rating industry group for Cullinan Oncology Inc are shown below.
Cullinan Oncology Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.5; made up of an environmental score of 4.0, social score of 3.2 and governance score of 6.4.
4.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 852 | Vaccibody AS | 4.6 | High |
| 852 | argenx SE | 4.6 | High |
| 868 | Cullinan Oncology Inc | 4.5 | High |
| 868 | CARsgen Therapeutics Holdings Ltd | 4.5 | High |
| 868 | Boiron SA | 4.5 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Cullinan Oncology Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Cullinan Oncology Inc report the average age of the workforce?
Sign up for free to unlockDoes Cullinan Oncology Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Cullinan Oncology Inc offer flexible work?
Sign up for free to unlockDoes Cullinan Oncology Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Cullinan Oncology Inc conduct supply chain audits?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Cullinan Oncology Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose water use targets?
Sign up for free to unlockDoes Cullinan Oncology Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Cullinan Oncology Inc have a product recall in the last two years?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Cullinan Oncology Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Cullinan Oncology Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose parental leave metrics?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Cullinan Oncology Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Cullinan Oncology Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Cullinan Oncology Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose its waste policy?
Sign up for free to unlockDoes Cullinan Oncology Inc report according to TCFD requirements?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose energy use targets?
Sign up for free to unlockDoes Cullinan Oncology Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Cullinan Oncology Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Cullinan Oncology Inc
These potential risks are based on the size, segment and geographies of the company.
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.